Disitamab vedotin, CAS 2136633-23-1

Product Description: Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity[1].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Huang L, Wang R, Xie K, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51-61./[2]Jiang J, et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. /[3]Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.

CAS Number: 2136633-23-1

Molecular Weight: 149000 (average)

Compound Purity: 99.0

Research Area: Cancer

Solubility: H2O

Target: Antibody-Drug Conjugates (ADCs);EGFR

• Artikelnummer: MEXHY-P9985-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P9985-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK